NEW YORK (GenomeWeb) – Sweden-based antibody array diagnostics firm Immunovia said today that it has started a multi-center prospective validation study of its Immray PanCan-d test for the early diagnosis of individuals at high risk for familial pancreatic cancer (FPC).

The longitudinal clinical study, called Panfam-1, will use the company's blood test to analyze 1,000 people at high risk for FPC over a period of three years. The subjects will be recruited at sites in the US and in Europe that offer FPC screening programs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.